ABSTRACT
Quality of life for men with prostate cancer is receiving increasing attention and, acknowledging that endocrine therapy remains conceptually a palliative treatment, many patients view preservation of quality of life as an equally important goal of therapy as prolongation of survival1. The issue of quality of life is further emphasized by the moves to initiate endocrine therapy earlier in the course of the disease and in younger men.
